Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)
about
Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative DiseasesSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.[Melanoma brain metastases : Treatment options].Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenograftsFactors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastasesABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expressionEfficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelActivation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.Melanoma brain metastases and vemurafenib: need for further investigation.Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastasesBRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer modelLong-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.Vemurafenib: in unresectable or metastatic melanoma.Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure.Biology in prevention and treatment of brain metastases.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.Toward precision medicine in glioblastoma: the promise and the challenges.Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.A systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015.Molecular insights into melanoma brain metastases.ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.Renal Drug Transporters and Drug Interactions.Clinical Pharmacokinetics of Vemurafenib.Challenges in the delivery of therapies to melanoma brain metastases.
P2860
Q28829017-4280EA74-8E2F-439E-ABF4-A6CDFACDD39FQ30239901-6CBED2A9-F008-46EA-8EE7-45DAB6C7F08BQ30251581-037D0F9D-CAAC-4521-976F-43A1144627A5Q30664269-5832779E-CFDF-4029-BE04-D63D0C8B5E18Q31098294-17583FB1-F7E6-4CB8-9B5E-97724A1A458CQ33888789-0F0A1F63-CE0F-42D6-ADFC-7037680E1B89Q33942964-88E40270-BCBA-440A-A943-DE99CD9B4B7CQ35171274-DA66910B-EB32-403C-A638-2C3DFE878878Q35317533-4DD941A2-8851-43DB-8CAF-1F4349593F37Q35799917-5044A09F-206E-4893-9F52-C0A224A2A25AQ35820476-6BBBDDF7-FFC2-4933-9B87-B95A46D87562Q35916658-F6E7592F-F391-47F5-A033-74C2E6A74FC3Q36186193-40EC45F0-C63D-4B82-93E3-190BDD55453DQ36251418-7BB8F8A3-9DD9-423F-9AA2-3B19B3EBCDCCQ36503052-FB738ADB-3E7F-4324-BDEA-18B1FDDFF895Q36512866-69404C9F-4942-4CB5-AC7D-F68E03832892Q36556926-56D2A605-0B5D-4279-B541-7C4A2F5CEC77Q36642420-752C0560-E780-4EE9-B368-26C7F620CD3CQ36654999-47E2B7BF-8D5A-4E00-8F2E-51F3A9662F7AQ36717122-80ABF3E9-ED51-4E2C-922A-92BE50BFE4FDQ37090142-1236858D-E825-4C7D-BC9A-CDFFBD1B9590Q37231972-47A39121-9AAE-47CE-A5E1-C5C51B7B0AEFQ37276052-DD6C5F9A-4E7F-4614-91EF-FA3F1DAB38D7Q37431085-473F376F-407A-41D6-A54E-8846DF52447DQ38040456-E5205170-C916-4281-B8F8-4A2B3DC00385Q38044958-AF79302C-1142-4552-980B-A127DACECA78Q38156192-D968BE51-49D7-424E-86FC-2D7E84DB5E6AQ38187646-87C3BFE3-0610-4441-B4A0-994B7DAC5B65Q38207943-70EE0FD9-9A67-4303-9395-6A36FB34FB0AQ38233105-D97ACD26-A8D1-4255-8D58-1DE0196C9A5BQ38351134-3E71F38D-B989-49DA-AB5C-92839426A3EEQ38454659-71D05C58-C122-4010-8FDA-BA1A44E8D2B9Q38715328-E881EE05-0998-4FDB-8CD9-A0CD2584C049Q38763312-307FFF64-86DE-4BFE-9D14-E002F9BBA164Q38764364-DCFEE687-3F03-4C3E-BC60-90C2ED60D2C8Q38887917-0E21B353-2A8B-4BF2-BEED-1DDF6FECE66AQ38975455-38D4BE5C-FF34-4740-B061-BBBC9A159B6BQ39140289-731B6DE0-D17E-4F18-8969-12FB5064E4C4Q39159365-A54EA785-76DD-44AA-99AF-3441F5723B83Q39331752-9F75620F-7CB4-49A8-9A78-1393C9A91714
P2860
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@ast
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@en
type
label
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@ast
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@en
prefLabel
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@ast
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@en
P2093
P2860
P356
P1476
Impact of P-glycoprotein (ABCB ...... hibitor: vemurafenib (PLX4032)
@en
P2093
Rajendar K Mittapalli
Ramola Sane
Shruthi Vaidhyanathan
William F Elmquist
P2860
P356
10.1124/JPET.112.192195
P407
P577
2012-03-27T00:00:00Z